Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07985819
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PF-07985819 is an investigational prophylactic mRNA (modRNA) vaccine being developed by Pfizer for the prevention of pandemic influenza. It uses a modified RNA platform to encode influenza hemagglutinin antigens, enabling host cells to transiently express these viral proteins and elicit protective humoral and cellular immune responses. Designed for intramuscular administration, this quadrivalent-like modRNA flu vaccine aims to offer rapid, adaptable manufacturing and enhanced immunogenicity against emerging pandemic influenza strains compared with traditional inactivated or live-attenuated vaccines.
- Other names
- pandemic influenza modified RNA vaccine
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on PF-07985819.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07985819.